Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|August 6, 2007
NACDS' new leader shares his goals for the industry
Steve Anderson is the new president of NACDS. Drug Topics asks Anderson a series of questions about the challenges ahead in a one-on-one interview.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
2
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
3
PPV23 Vaccination Found to Not Reduce Cardiovascular Risk
4
Social Media Best Practices for Pharmacists: Why Visibility Matters
5